NCT00204373

Treatment of Zollinger-Ellison Syndrome With Prevacid

Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Charles Mel Wilcox, MD · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

Detailed description

The aim of this protocol is to study the medical management of acid hypersecretory states including Zollinger-Ellison using Prevacid. The immediate objective is to heal peptic ulcers and eliminate symptoms and in the long term to prevent relapse of symptoms, lesions and complications. Other objectives include observation of the efficacy in controlling gastric acid production and of the safety of high dose, long-term use of Prevacid.

Conditions

• Zollinger-Ellison Syndrome
• Multiple Endocrine Neoplasia

Interventions

Type	Name	Description
DRUG	Lansoprazole (Prevacid)	Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.

Timeline

• Start date: 2003-03-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2005-09-20
• Last updated: 2012-10-30
• Results posted: 2012-10-19